Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutically acceptable salt, crystal form and preparation method of pyrazoloheteroaryl derivatives

A technology for medicinal salts and crystal forms, applied in the field of medicinal salts of pyrazoloheteroaryl derivatives, can solve the problems of poor product stability, difficult filtration, easy caking and the like, and achieves high chemical stability, Stable production process and little change in purity

Active Publication Date: 2021-09-03
JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Generally speaking, amorphous pharmaceutical products have no regular crystal structure and often have other defects, such as poor product stability, fine crystallization, difficult filtration, easy agglomeration, poor fluidity, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutically acceptable salt, crystal form and preparation method of pyrazoloheteroaryl derivatives
  • Pharmaceutically acceptable salt, crystal form and preparation method of pyrazoloheteroaryl derivatives
  • Pharmaceutically acceptable salt, crystal form and preparation method of pyrazoloheteroaryl derivatives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0132] Weigh 10 mg of the compound shown in formula (I) and add it to the reaction flask, add 0.25 ml of acetonitrile, heat up to 50 ° C, add 3.05 mg of fumaric acid, keep stirring for 30 min, collect the reaction product, and dry it in vacuum at 40 ° C to obtain the formula (I ) A crystal form of compound fumarate shown in ). Its X-ray diffraction pattern is shown in figure 1 , see the TGA spectrum Figure 13 , and its characteristic peak positions are shown in the table below:

[0133] Table 1. Characteristic peaks of crystal form A of fumarate

[0134]

Embodiment 2

[0136] Weigh 10 mg of the compound represented by formula (I) and add it to the reaction flask, add 0.25 ml of ethyl acetate, heat up to 50 ° C, add 3.05 mg of fumaric acid, keep stirring for 30 min, collect the reaction product, and dry it in vacuum at 40 ° C to obtain the formula (1) The B crystal form of the compound fumarate shown in (I). Its X-ray diffraction pattern is shown in figure 2 , see the TGA spectrum Figure 14 , and its characteristic peak positions are shown in the table below:

[0137] Table 2. Characteristic peaks of fumarate B crystal form

[0138]

Embodiment 3

[0140] Weigh 10 mg of the compound shown in formula (I) and add it to the reaction flask, add 0.25 ml of p-xylene, heat up to 50 ° C, add 3.05 mg of fumaric acid, keep stirring for 30 min, collect the reaction product, and dry it in vacuum at 40 ° C to obtain the formula (1) The C crystal form of the shown compound fumarate. Its X-ray diffraction pattern is shown in image 3 , and its characteristic peak positions are shown in the table below:

[0141] Table 3. Characteristic peaks of crystal form C of fumarate

[0142]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutically acceptable salt, crystal form and preparation method of pyrazolo heteroaryl derivatives. The new pharmaceutically acceptable salt and the new crystal form of the present invention have good stability and can be better used in clinical treatment.

Description

technical field [0001] The invention relates to a pharmaceutically acceptable salt, crystal form, preparation method and pharmaceutical application of pyrazoloheteroaryl derivatives. Background technique [0002] Toll-like receptors (toll-like receptors; TLRs) are an important class of protein molecules involved in innate immunity. TLRs are monomeric transmembrane non-catalytic receptors, usually expressed in sentinel cells such as macrophages and dendritic cells, which can recognize structurally conserved molecules produced by microorganisms. Once these microbes break through a physical barrier such as the skin or intestinal mucosa, they are recognized by TLRs, which in turn activate an immune cell response. (Mahla, RS. et al., Front Immunol. 4:248 (2013)). The ability of the immune system to widely recognize pathogenic microorganisms is partly due to the widespread existence of Toll-like immune receptors. [0003] There are at least 10 different TLRs in mammals. Ligand...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D487/04A61P31/12A61P31/14A61P31/16A61P31/18A61P35/00A61P11/02A61P11/06A61P1/04A61P1/16A61K31/519
CPCA61P1/04A61P1/16A61P11/02A61P11/06A61P31/12A61P31/14A61P31/16A61P31/18A61P35/00C07B2200/13C07D487/04
Inventor 曹笑立杜振兴王立坤
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products